Incidence of WHO stage 3 and 4 conditions following initiation of anti-retroviral therapy in resource limited settings

PLoS One. 2012;7(12):e52019. doi: 10.1371/journal.pone.0052019. Epub 2012 Dec 20.


Objectives: To determine the incidence of WHO clinical stage 3 and 4 conditions during early anti-retroviral therapy (ART) in resource limited settings (RLS).

Design/setting: A descriptive analysis of routine program data collected prospectively from 25 Médecins Sans Frontières supported HIV treatment programs in eight countries between 2002 and 2010.

Subjects/participants: 35,349 study participants with median follow-up on ART of 1.33 years (IQR 0.51-2.41).

Outcome measures: Incidence in 100 person-years of WHO stage 3 or 4 conditions during 5 periods after ART initiation. Diagnoses of conditions were made according to WHO criteria and relied upon clinical assessments supported by basic laboratory investigations.

Results: The incidence of any WHO clinical stage 3 or 4 condition over 3 years was 40.02 per 100 person-years (31.77 for stage 3 and 8.25 for stage 4). The incidence of stage 3 and 4 conditions fell by over 97% between months 0-3 and months 25-36 (77.81 to 2.40 for stage 3 and 28.70 to 0.64 for stage 4). During months 0-3 pulmonary tuberculosis was the most common condition diagnosed in adults (incidence 22.24 per 100 person-years) and children aged 5-14 years (25.76) and oral candidiasis was the most common in children <5 years (25.79). Overall incidences were higher in Africa compared with Asia (43.98 versus 12.97 for stage 3 and 8.98 versus 7.05 for stage 4 conditions, p<0.001). Pulmonary tuberculosis, weight loss, oral and oesophageal candidiasis, chronic diarrhoea, HIV wasting syndrome and severe bacterial infections were more common in Africa. Extra-pulmonary tuberculosis, non-tuberculous mycobacterial infection, cryptococcosis, penicilliosis and toxoplasmosis were more common in Asia.

Conclusions: The incidence of WHO stage 3 and 4 conditions during the early period after ART initiation in RLS is high, but greatly reduces over time. This is likely due to both the benefits of ART and deaths of the sickest patients occurring shortly after ART initiation. Access to appropriate disease prevention tools prior to ART, and early initiation of ART, are important for their prevention.

MeSH terms

  • Adult
  • Africa
  • Age Factors
  • Anti-Retroviral Agents*
  • Asia
  • CD4 Lymphocyte Count
  • Developing Countries*
  • Female
  • HIV Infections / diagnosis*
  • HIV Infections / drug therapy*
  • HIV Infections / epidemiology
  • Health Resources*
  • Humans
  • Incidence
  • Male
  • Severity of Illness Index


  • Anti-Retroviral Agents

Grant support

The authors have no support or funding to report.